These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 19552743)
1. Orphan drug development is not taking off. Joppi R; Bertele V; Garattini S Br J Clin Pharmacol; 2009 May; 67(5):494-502. PubMed ID: 19552743 [No Abstract] [Full Text] [Related]
2. Orphan economics: the downside of supplyside pharmacology. Samson K Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669 [No Abstract] [Full Text] [Related]
3. The Orphan Drug Act: how well is it working? Groft SC Am Pharm; 1985 Sep; NS25(9):52-4. PubMed ID: 4050674 [No Abstract] [Full Text] [Related]
4. March on, not in. Nat Med; 2011 May; 17(5):515. PubMed ID: 21546944 [No Abstract] [Full Text] [Related]
5. New products highlight ambiguity of orphan drug law. Reid B Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896 [No Abstract] [Full Text] [Related]
6. [Effectivity of data obtention previous to drug commercialization: utopy or reality?]. Soto Alvarez J Med Clin (Barc); 2006 Nov; 127(19):736-7. PubMed ID: 17198650 [No Abstract] [Full Text] [Related]
7. China's counterfeit medicine trade booming. Lewis K CMAJ; 2009 Nov; 181(10):E237-8. PubMed ID: 19805500 [No Abstract] [Full Text] [Related]
8. The Orphan Products Board of the Department of Health & Human Services. Crooks GM Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294 [No Abstract] [Full Text] [Related]
9. [Pharmacotherapy between theory and practice]. Stricker BH Ned Tijdschr Geneeskd; 1995 Nov; 139(45):2295-6. PubMed ID: 7501059 [No Abstract] [Full Text] [Related]
10. Adoption agent. Peota C Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583 [No Abstract] [Full Text] [Related]
11. Congress, the FDA, and the fair development of new medications for children. McKinney RE Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299 [No Abstract] [Full Text] [Related]
12. Can lifecycle management safeguard innovation in the pharmaceutical industry? Hering S; Loretz B; Friedli T; Lehr CM; Stieneker F Drug Discov Today; 2018 Dec; 23(12):1962-1973. PubMed ID: 30342247 [TBL] [Abstract][Full Text] [Related]
13. Regulatory watch: Where do new medicines originate from in the EU? Lincker H; Ziogas C; Carr M; Porta N; Eichler HG Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298 [No Abstract] [Full Text] [Related]
14. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits. Lee J Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725 [No Abstract] [Full Text] [Related]
15. Generic Pharmaceutical Industry Association Orphan Drug Institute. Haddad W Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298 [No Abstract] [Full Text] [Related]
16. [Orphan drugs from the perspective of research-based pharmaceutical and biotech companies]. Sydow S; Throm S Internist (Berl); 2019 Apr; 60(4):405-410. PubMed ID: 30859276 [No Abstract] [Full Text] [Related]
18. [Orphan Drugs: Underrated Opportunities for The Developers in Europe]. Tillet Y; Maillols-Perroy AC Therapie; 2015; 70(4):351-7. PubMed ID: 25997721 [TBL] [Abstract][Full Text] [Related]
19. The Antiepileptic Drug Development Program: an example of government-industry collaboration. White BG Prog Clin Biol Res; 1985; 197():83-93. PubMed ID: 4070302 [TBL] [Abstract][Full Text] [Related]
20. Current status of orphan disease drug development. Thoene JG Curr Opin Pediatr; 1994 Apr; 6(2):209-12. PubMed ID: 8032402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]